STRATA CRITICAL MEDICAL INC CLASS (SRTA)
Health Care · Time-critical medical logistics and organ transplant services · NASDAQ
A time-critical logistics and clinical services provider offering integrated air/ground organ transport, surgical organ recovery, and cardiac perfusion solutions to the U.S. transplant ecosystem.
What STRATA CRITICAL MEDICAL INC CLASS does
Strata Critical Medical is a time-critical logistics and medical services provider serving the U.S. healthcare transplant industry. The company operates one of the nation's largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, providing integrated "one call" solutions for donor organ recovery. It operates two segments: Logistics (air and ground organ transportation, organ placement coordination under the Trinity brand) and Clinical (surgical organ recovery, normothermic regional perfusion, organ preservation, and cardiac perfusion services under the Keystone brand).
Themes: Organ transplant logistics and services, Critical care medical services, Cardiac surgery support / perfusion, Healthcare supply chain
Fundamentals
- Price$6.24 as of 2026-08-21 close
- Market cap$552M as of 2026-08-21
- 1-year return+47.2% 2025-08-21 close $4.24 → 2026-08-21 close $6.24
- P/E13.14 as of 2026-08-24
- Net margin+15.7% as of 2026-08-24
- Gross margin-40.4% as of 2026-08-24
- ROE+14.3% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+18.8% as of 2026-08-24
- Revenue CAGR (3y)+10.5% SEC XBRL
- Beta2.47 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How SRTA compares in its sector
- price-to-earnings ratiobottom 25% 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How STRATA CRITICAL MEDICAL INC CLASS looks technically
STRATA CRITICAL MEDICAL INC CLASS (SRTA) is trading 25.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 49 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 66, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day high, pushing above its recent trading range. It is 0.8% below its 52-week high (its highest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 25.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +25.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $5.47 | $5.47 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.99 | $4.99 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 49 trading days ago — a "golden cross", a bullish long-term signal | 49 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 25.2% above | +25.1% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with buyers in control | 29.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 66, neither overbought (above 70) nor oversold (below 30) | 66.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($5.32 to $6.29) — its "stochastic" reading is 95 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 94.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 15 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $6.29 | $6.29 |
|---|---|---|
| From the 52-week high | it is 0.8% below its 52-week high (its highest price of the past year) | -0.8% |
| Above the 52-week low | it is 69.8% above its 52-week low (its lowest price of the past year) | +69.8% |
| Below the 52-week high | it is at or near its highest point of the past year | 0.8% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $19.88 (set on 2021-02-16) | $19.88 |
| Given back of the 52-week move | over the past year its closes ranged ($3.77 to $6.24), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.63 to $4.71. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 68.6% below its all-time high | -68.6% |
| Nearest price level | it is trading 2.4% above a support level at $6.09 — a price it turned at twice since 2026-06-16, most recently on 2026-08-11. Since 2024-08-21 it has 19 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.4% |
| All-time low | its lowest closing price on record is $2.06 (set on 2023-10-30) | $2.06 |
| Above the all-time low | it is 202.9% above its all-time low | +202.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 78% of it) | 78th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.252 between its high and its low — about 4.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.252 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $4.87 and $6.44 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $4.87 – $5.66 – $6.44 |
| Typical daily range (% of price) | its price moves about 4.0% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.0% |
| Stretch from the 200-day average | it is trading 5.0 daily ranges above its 200-day average price (25.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.01× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 1.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.5% |
|---|---|---|
| Gap filled | a 2.7% gap down opened on 2026-08-04 has been "filled" 13 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 13 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +9.47% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 18.6 percentage points (the stock gained 20.9% while the market gained 2.3%) | +18.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 4.5 percentage points (the stock gained 7.6% while the market gained 3.1%) | +4.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 27.6 percentage points (the stock gained 38.7% while the market gained 11.1%) | +27.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 26.7 percentage points (the stock gained 47.2% while the market gained 20.5%) | +26.7% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 15% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 1.2% of the share price, which is taken to mean a barrier that gives way easily. | +14.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 20% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $5.19 — a volume-weighted average of daily closes over 150 sessions, not a true tick-by-tick VWAP. | +20.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% above the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $5.86 — a volume-weighted average of daily closes over 14 sessions, not a true tick-by-tick VWAP. | +6.6% |
Price levels it has turned at before
SRTA last closed at $6.24 on 2026-08-21. Since 2024-08-21 it has turned at 19 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $6.09 | Support | 2.4% below the last close | turned there twice · 2026-06-16 to 2026-08-11 |
| $5.99 | Support | 4.1% below the last close | turned there three times · 2025-09-19 to 2026-01-08 |
| $5.53 | Support | 11.5% below the last close | turned there twice · 2025-10-06 to 2026-07-16 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Near the 52-week high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$9.56 range $8.00 – $12.75; median $8.75
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["Heavy reliance on transplant centers, organ procurement organizations, and hospital customers; concentration of revenue in a critical but limited market segment","Regulatory and compliance requirements specific to organ transport, medical device operation, and healthcare; changes in transplant protocols or regulations could impact service demand","Operational dependencies on third-party aircraft operators and service providers; disruptions to partner networks or capacity constraints could affect service delivery"]
What changed in the latest 10-Q
AI-assisted comparison of SRTA's 10-Q filed 2026-05-06 against the prior one filed 2025-11-10.
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 5 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($29273) — 1 selling insider
- Last 90 days0 buys · 5 sells ($449600) — 5 selling insiders
- Last 180 days0 buys · 8 sells ($831867) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-10. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about SRTA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding SRTA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 14,252,656
- Reported value $59,576,103
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
SRTA had 4,201,679 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
SRTA had 4.75% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.32 days to cover at the same settlement.
- Reported short interest (shares) 4,201,679
- Short interest (% of shares outstanding) 4.75%
- Prior settlement (shares) 4,327,351
- Reported change -2.9%
- Days to cover (reported) 4.32
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Air Methods
- LifeNet Health
- SpecialtyCare
- Perfusion Solutions
- Global Medical Response
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Frequently asked questions
What does STRATA CRITICAL MEDICAL INC CLASS (SRTA) do?
Strata Critical Medical is a time-critical logistics and medical services provider serving the U.S. healthcare transplant industry. The company operates one of the nation's largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, providing integrated "one call" solutions for donor organ recovery.
What sector is STRATA CRITICAL MEDICAL INC CLASS (SRTA) in?
STRATA CRITICAL MEDICAL INC CLASS (SRTA) is classified in the Health Care sector. Its industry is Time-critical medical logistics and organ transplant services. It trades on NASDAQ.
Who are STRATA CRITICAL MEDICAL INC CLASS's (SRTA) competitors?
Notable peers of STRATA CRITICAL MEDICAL INC CLASS (SRTA) include Air Methods, LifeNet Health, SpecialtyCare, Perfusion Solutions and Global Medical Response. This peer set is informational only — not financial advice.
Is STRATA CRITICAL MEDICAL INC CLASS (SRTA) overbought or oversold right now?
STRATA CRITICAL MEDICAL INC CLASS (SRTA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 66, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SRTA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.